Verification Opinion on the Dilution of Immediate Returns and Remedial Measures for the Current Transaction
Beijing Leadman Biochemistry Co., Ltd. (hereinafter "the Company" or "the Listed Company") intends to acquire a total of 235,040,700 shares (representing 61.50% of the issued shares) of Beijing Sansheng Xiangrui Biological Products Co., Ltd. (hereinafter "Sansheng Xiangrui") held by Hainan Baimai Investment Co., Ltd., Hainan Sansheng Baijiahui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) through a cash payment (hereinafter "the Current Transaction").
CSC Financial Co., Ltd. (hereinafter "the Independent Financial Advisor"), as the independent financial advisor for this transaction, has reviewed the impact of the transaction on immediate returns, the preventive and remedial measures, and relevant commitments in accordance with the requirements of the "Opinions of the General Office of the State Council on Further Strengthening the Protection of the Lawful Rights and Interests of Small and Medium Investors in the Capital Market," the "Opinions of the State Council on Further Promoting the Healthy Development of the Capital Market," and the "Guiding Opinions on Matters Concerning the Dilution of Immediate Returns in Initial Public Offerings, Refinancing, and Major Asset Restructurings."